Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

ClinicalTrials.gov ID: NCT02058160

Public ClinicalTrials.gov record NCT02058160. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 6:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.

Study identification

NCT ID
NCT02058160
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
736 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2014 (Type not available)
Primary completion
Jul 2015 (Actual)
Completion
Jul 2015 (Actual)
Last update posted
May 9, 2017

2014 – 2015

United States locations

U.S. sites
108
U.S. states
34
U.S. cities
94
Facility City State ZIP Site status
Investigational Site Number 840607 Birmingham Alabama 35205 —
Investigational Site Number 840570 Sun City Arizona 85351 —
Investigational Site Number 840562 Tempe Arizona — —
Investigational Site Number 840577 Tucson Arizona 85723 —
Investigational Site Number 840517 Little Rock Arkansas 72205 —
Investigational Site Number 840537 Little Rock Arkansas 72205 —
Investigational Site Number 840568 Bell Gardens California 90201 —
Investigational Site Number 840550 Chino California 91710 —
Investigational Site Number 840529 Chula Vista California 91911 —
Investigational Site Number 840623 Corona California 92879 —
Investigational Site Number 840566 Fresno California 93720 —
Investigational Site Number 840552 Greenbrae California 94904 —
Investigational Site Number 840578 Lancaster California 93534 —
Investigational Site Number 840626 Los Angeles California 90017 —
Investigational Site Number 840581 Los Angeles California 90057 —
Investigational Site Number 840621 Mission Viejo California 92691 —
Investigational Site Number 840511 Northridge California 91325 —
Investigational Site Number 840573 Palm Springs California 92262 —
Investigational Site Number 840559 Port Hueneme California 93041 —
Investigational Site Number 840536 San Ramon California 94583 —
Investigational Site Number 840567 Santa Ana California 92704 —
Investigational Site Number 840569 Tarzana California 91356 —
Investigational Site Number 840572 West Hills California 91345 —
Investigational Site Number 840582 Aurora Colorado 80045 —
Investigational Site Number 840509 Denver Colorado 80246 —
Investigational Site Number 840549 Wilmington Delaware 19713 —
Investigational Site Number 840510 Miami Florida 33156-7563 —
Investigational Site Number 840521 New Port Richey Florida 34652 —
Investigational Site Number 840602 Ocala Florida 34471 —
Investigational Site Number 840538 Ocoee Florida 34761 —
Investigational Site Number 840534 Palm Harbor Florida 34684 —
Investigational Site Number 840594 Atlanta Georgia 30322 —
Investigational Site Number 840614 Columbus Georgia 31904 —
Investigational Site Number 840501 Lawrenceville Georgia 30046 —
Investigational Site Number 840525 Roswell Georgia 30076 —
Investigational Site Number 840588 Idaho Falls Idaho 83404 —
Investigational Site Number 840580 Arlington Heights Illinois 60005 —
Investigational Site Number 840519 Chicago Illinois 60607 —
Investigational Site Number 840612 Chicago Illinois 60616 —
Investigational Site Number 840556 Springfield Illinois 62704 —
Investigational Site Number 840543 Avon Indiana 46123 —
Investigational Site Number 840565 Evansville Indiana 47713 —
Investigational Site Number 840585 Evansville Indiana 47714 —
Investigational Site Number 840615 Evansville Indiana 47714 —
Investigational Site Number 840563 Indianapolis Indiana 46202 —
Investigational Site Number 840507 Indianapolis Indiana 46260 —
Investigational Site Number 840516 Louisville Kentucky 40213 —
Investigational Site Number 840595 Lewiston Maine 04240 —
Investigational Site Number 840520 Baltimore Maryland 21237 —
Investigational Site Number 840560 Baltimore Maryland 21237 —
Investigational Site Number 840522 Rockville Maryland 20852 —
Investigational Site Number 840505 Dearborn Michigan 48124 —
Investigational Site Number 840575 Flint Michigan 48504 —
Investigational Site Number 840564 Minneapolis Minnesota 55416 —
Investigational Site Number 840558 Butte Montana 59701 —
Investigational Site Number 840506 Omaha Nebraska 68131 —
Investigational Site Number 840600 Henderson Nevada 89074 —
Investigational Site Number 840532 Las Vegas Nevada 89119 —
Investigational Site Number 840599 Las Vegas Nevada 89148 —
Investigational Site Number 840539 Nashua New Hampshire 03063 —
Investigational Site Number 840576 Albuquerque New Mexico 87131 —
Investigational Site Number 840583 Jamaica New York 11432 —
Investigational Site Number 840531 New Hyde Park New York 11042 —
Investigational Site Number 840557 Syracuse New York 13214-2016 —
Investigational Site Number 840541 Durham North Carolina 27710 —
Investigational Site Number 840604 Greenville North Carolina 27858 —
Investigational Site Number 840540 Hickory North Carolina 28601 —
Investigational Site Number 840513 Morehead City North Carolina 28557 —
Investigational Site Number 840592 Salisbury North Carolina 28144 —
Investigational Site Number 840535 Wilmington North Carolina 28401 —
Investigational Site Number 840515 Winston-Salem North Carolina 27103 —
Investigational Site Number 840579 Columbus Ohio 43213 —
Investigational Site Number 840524 Dayton Ohio 45439 —
Investigational Site Number 840503 Maumee Ohio 43537 —
Investigational Site Number 840618 Eugene Oregon 97404 —
Investigational Site Number 840610 Philadelphia Pennsylvania 19107 —
Investigational Site Number 840551 Smithfield Pennsylvania 15478 —
Investigational Site Number 840584 Tipton Pennsylvania 16684 —
Investigational Site Number 840622 Charleston South Carolina 29407 —
Investigational Site Number 840611 Rapid City South Dakota 57701 —
Investigational Site Number 840605 Amarillo Texas 79106 —
Investigational Site Number 840553 Austin Texas 78731 —
Investigational Site Number 840598 Austin Texas 78731 —
Investigational Site Number 840502 Corpus Christi Texas 78404 —
Investigational Site Number 840601 Dallas Texas 75208 —
Investigational Site Number 840586 Dallas Texas 75216 —
Investigational Site Number 840547 Dallas Texas 75230 —
Investigational Site Number 840530 Dallas Texas 75231 —
Investigational Site Number 840545 Dallas Texas 75246 —
Investigational Site Number 840554 Edinburg Texas 78539 —
Investigational Site Number 840544 Houston Texas 77030 —
Investigational Site Number 840514 Hurst Texas 76054 —
Investigational Site Number 840617 N Richland Hill Texas 76180 —
Investigational Site Number 840512 Draper Utah 84020 —
Investigational Site Number 840591 Murray Utah 84123 —
Investigational Site Number 840526 Ogden Utah 84405 —
Investigational Site Number 840597 Orem Utah 84058 —
Investigational Site Number 840590 Salt Lake City Utah 84102 —
Investigational Site Number 840613 Burlington Vermont 05401 —
Investigational Site Number 840504 Chesapeake Virginia 23321 —
Investigational Site Number 840561 Norfolk Virginia 23510 —
Investigational Site Number 840625 Norfolk Virginia 23510 —
Investigational Site Number 840606 Richmond Virginia 23227 —
Investigational Site Number 840608 Salem Virginia 24153 —
Investigational Site Number 840571 Federal Way Washington 98003 —
Investigational Site Number 840593 Spokane Washington 99220 —
Investigational Site Number 840609 Tacoma Washington 98415-0299 —
Investigational Site Number 840546 Milwaukee Wisconsin 53209-0996 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 128 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02058160, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 9, 2017 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02058160 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →